• PL-PULSEX-V55
1 1

Dual growth-hormone-axis research peptide blend

PULSE-X CJC-1295 + Ipamorelin

PULSE-X CJC-1295 + Ipamorelin

CJC-1295 (No DAC / Modified GRF 1-29) + Ipamorelin

Dhs. 0.00 AED
Dhs. 0.00 AED
Sale Sold out
Strength

PULSE-X combines a short-acting GHRH analog with a ghrelin-receptor agonist for laboratory research on complementary pituitary growth-hormone signaling pathways.

Specifications

Active material
CJC-1295 (No DAC / Modified GRF 1-29) + Ipamorelin
Available variant(s)
5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin
Form
Lyophilized powder blend
Container
3 mL vial
CAS number(s)
The blend has no single CAS. CJC-1295 No DAC 863288-34-0; Ipamorelin 170851-70-4
Molecular formula
The blend has no single formula. CJC-1295 C152H252N44O42; Ipamorelin C38H49N9O5
Molecular weight
CJC-1295 3367.9 g/mol; Ipamorelin 711.85 g/mol
Sequence / structure
Two-component blend; identities and ratio must be confirmed separately by analytical testing

What this material is studied for
  • GHRH receptor and ghrelin receptor (GHS-R1a) signaling studies.
  • Growth hormone pulse and downstream IGF-axis biomarker research.
  • Comparative single-agent versus combination studies in validated models.

Scientific context

CJC-1295 without DAC activates the GHRH receptor, while ipamorelin activates the ghrelin receptor. Both pathways can stimulate pituitary growth-hormone release, but published human randomized evidence for this exact combination is lacking.

Storage and handling

Store according to the product label instructions. Protect from light. Keep sealed until research use.

Disclaimer

For laboratory research use only. Not for human or veterinary use. Not a food, drug, cosmetic or dietary supplement. Not intended to diagnose, treat, cure or prevent any disease. Purchasers are responsible for lawful handling and use by qualified personnel.

View full details